Open-Label Extension Protocol to SNK01-AD01 Study
NCT07228078 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30
Last updated 2025-11-13
Summary
Open-Label Extension Protocol to SNK01-AD01 Study
Conditions
- Alzheimer Disease
Interventions
- BIOLOGICAL
-
SNK01
SNK01 is a novel cell-based, patient specific ex vivo expanded autologous natural killer (NK) cell, immunotherapeutic drug
Sponsors & Collaborators
-
NKGen Biotech, Inc.
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 40 Years
- Max Age
- 85 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-06-30
- Primary Completion
- 2028-04-30
- Completion
- 2028-04-30
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
NCT01224106 ·Status: COMPLETED ·Phase: PHASE3
-
Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects
NCT06304883 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD)
NCT04374253 ·Status: TERMINATED ·Phase: PHASE3
-
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
NCT01723826 ·Status: COMPLETED ·Phase: PHASE2
-
To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients
NCT01023685 ·Status: COMPLETED ·Phase: PHASE2
-
Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age
NCT02576639 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)
NCT05262023 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of RO7105705 in Healthy Participants and Participants With Mild-to-Moderate Alzheimer's Disease
NCT02820896 ·Status: COMPLETED ·Phase: PHASE1
-
A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease
NCT05804383 ·Status: COMPLETED ·Phase: PHASE1
-
Long Term Extension Safety Study in Patients With Dementia of the Alzheimer's Type Who Completed Study CPC-001-07
NCT02434666 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 1 Study of the Safety, Tolerability and Pharmacokinetics of ABT-126 in Subjects With Alzheimer's Disease
NCT01482845 ·Status: COMPLETED ·Phase: PHASE1
-
Study of the Effect of SR57667B in Patients With Alzheimer's Disease
NCT00285025 ·Status: COMPLETED ·Phase: PHASE2
-
Long-Term Safety Extension With SR57667B in Patients With Alzheimer's Disease
NCT00285077 ·Status: COMPLETED ·Phase: PHASE2
-
An Open-label Extension to Evaluate the Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease
NCT00219232 ·Status: COMPLETED ·Phase: PHASE3
-
Safety, Tolerability and Pharmacokinetics of AD16 Tablets in Adult Healthy Subjects After Single Administration
NCT05787028 ·Status: COMPLETED ·Phase: PHASE1
-
Prospective Analysis of the Use of N-Acetylcysteine and Vitamins in the Treatment of TBI in Geriatric Patients
NCT04291066 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of LY2886721 in Healthy Participants and Participants Diagnosed With Alzheimer's Disease
NCT01807026 ·Status: COMPLETED ·Phase: PHASE1
-
Study of IGC-AD1 in Subjects With Dementia Due to Alzheimer's Disease
NCT04749563 ·Status: COMPLETED ·Phase: PHASE1
-
Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects
NCT05363293 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Clinical Trial to Compare Forms of MK-1167 in Healthy People (MK-1167-011)
NCT07334860 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Recombinant Human Serum Albumin in the Treatment of AD (Alzheimer Disease) Exploratory Clinical Trials
NCT06489015 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1
-
A Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anti-Abeta (MABT5102A) in Patients With Alzheimer's Disease
NCT00736775 ·Status: COMPLETED ·Phase: PHASE1
-
MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011)
NCT00420420 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease
NCT07214727 ·Status: RECRUITING ·Phase: PHASE1
-
Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)
NCT06245031 ·Status: ENROLLING_BY_INVITATION ·Phase: NA